Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 5, 2013

Waters Corporation Announces CEO Transition Plan

Author(s)Melanie Sena

CEO of Waters Corporation will retire within in the next two years.

Waters Corporation announced that Douglas A. Berthiaume will retire as CEO within the next two years.

The company’s board of directors has appointed a succession planning committee that will guide the process of selecting a successor and plans to hire an executive search firm to assist in a search, which will consider both internal and external candidates.

Berthiaume, who is 64, was appointed president and CEO of Waters Corporation in 1994 when the business was separated from Millipore, and assumed the additional role of chairman in 1996.

Source: Waters Corporation


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.